MedTrace Logo

Abilify Therapy for Reducing Comorbid Substance Abuse

NCT00208169 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2007-08-24

No results posted yet for this study

Summary

It is hypothesized that the use of aripiprazole (Abilify) in patients with alcohol and/or drug dependence with comorbid psychiatric conditions will lead to:

* Reduction in the amount of alcohol and/or drugs used as measured by the Time Line Follow Back (TLFB) and the Addiction Severity Index (ASI)
* Reduction in cravings for alcohol and drugs as measured by the Penn Alcohol Craving Scale
* Reduction in symptoms of co-morbid psychiatric disorders compared to before starting aripiprazole.

Conditions

Interventions

DRUG

Aripiprazole

Sponsors & Collaborators

Principal Investigators

  • Pirzada S. Sattar, M.D. · Creighton University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2005-03-31
Completion
2007-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00208169 on ClinicalTrials.gov